

## HLA-A\*11:01&amp;B2M&amp;KRAS G12C (VVGACGVGK) Monomer Protein, Human, MHC (His &amp; Avi)

## General Information

Synonyms:	C-K-RAS;KI-RAS;KRAS1;K-RAS4A;KRAS2;CFC2;MHC;NS3;K-RAS2B;NS;K-RAS4B;K-Ras 2;K-RAS2A;RASK2;KRAS;GTPase Kras;RALD
Protein Construction:	Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVGACGVGK peptide
Species:	Human
Expression Host:	HEK293 Cells
Accession:	AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVGACGVGK
Molecular Weight:	The protein has a predicted MW of 50.30 kDa. Due to glycosylation, the protein migrates to 53-63 kDa based on Tris-Bis PAGE result.

## QC Testing

Biological Activity:	Activity has not been tested. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first.
Purity:	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Endotoxin:	< 1.0 EU/ $\mu$ g of the protein as determined by the LAL method.
Formulation:	Lyophilized from a solution filtered through a 0.22 $\mu$ m filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.

## Preparation and Storage

## Reconstitution:

Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100  $\mu$ g/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

## Stability &amp; Storage:

Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

## Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

## Protein Background

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

Reference

Wu HZ, et al. KRAS: A Promising Therapeutic Target for Cancer Treatment. Curr Top Med Chem. 2019;19(23):2081-2097. doi: 10.2174/1568026619666190905164144. PMID: 31486755.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481